Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2.
CHICAGO — Vorasidenib significantly improved PFS while delaying time to next intervention among certain patients with grade 2 isocitrate dehydrogenase 1- or 2-mutant glioma, according to data presented at ASCO Annual Meeting.The findings, published simultaneously in The New England Journal of Medicine, showed efficacy across all patient subgroups.